Market News

Follow the latest financial and economic news, market updates, reports, and analysis on PipVero.

Source: Seeking Alpha News Agency
1 month ago
Stock Medium Importance
Dine Brands Global Is Cheap, But The Long-Term Picture Isn't Worth Banking On Yet

Dine Brands Global Is Cheap, But The Long-Term Picture Isn't Worth Banking On Yet

Dine Brands Global reported Q2 2026 revenue above expectations, but EPS and adjusted EPS missed analyst estimates. While DIN remains objectively cheap on both absolute and relative valuation, persistent declines in profitability and rising net debt temper enthusiasm. Growth in IHOP system-wide sales and dual-branded locations offers long-term opportunity, but near-term cash flow and margin pressures persist.

Related Symbols 1
GTLL GTLL
Source: Seeking Alpha
Visit Source
0 0 0
Read More
Comment
Source: Seeking Alpha News Agency
1 month ago
Stock Medium Importance
Bed Bath & Beyond: An Unprecedented, Unfocused Plan

Bed Bath & Beyond: An Unprecedented, Unfocused Plan

Bed Bath & Beyond, soon Neighborhood Intelligence, is a qualitative turnaround bet centered on CEO Marcus Lemonis's ambitious multi-pillar strategy. Lemonis envisions a synergistic ecosystem spanning retail, financial, and home services, but customer retention and cross-sell logic remain unproven and historically fraught. The investment case is highly speculative; the grand strategy and basic turnaround both face daunting execution risks with little evidence of early traction.

Related Symbols 1
BBBY BBBY
Source: Seeking Alpha
Visit Source
0 0 0
Read More
Comment
Source: MarketBeat News Agency
1 month ago
Stock Medium Importance
Exelixis Q2 Earnings Call Highlights

Exelixis Q2 Earnings Call Highlights

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program for the drug candidate.

Related Symbols 1
EXEL EXEL
Source: MarketBeat
Visit Source
Official Partner ITBFX Start Trading
0 0 0
Read More
Comment
Source: Seeking Alpha News Agency
1 month ago
Stock Medium Importance
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

Related Symbols 1
RIGL RIGL
Source: Seeking Alpha
Visit Source
0 0 0
Read More
Comment
Source: Reuters News Agency
1 month ago
Stock Medium Importance
Australia's Beach Energy swings to annual profit, shares slide on weak production outlook

Australia's Beach Energy swings to annual profit, shares slide on weak production outlook

Beach Energy posted an annual profit on Thursday, a sharp turnaround from a year-earlier loss, although ​shares of the Australian oil and gas producer slipped more than 6% as ‌investors focused on its soft production outlook.

Related Symbols 1
BCHEY BCHEY
Source: Reuters
Visit Source
0 0 0
Read More
Comment
Source: Accesswire News Agency
1 month ago
Stock Medium Importance
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA for adults 50 years of age and older.

Related Symbols 1
MRNA MRNA
Source: Accesswire
Visit Source
Official Partner ITBFX Start Trading
0 0 0
Read More
Comment
Source: Newsfile Corp News Agency
1 month ago
Stock Medium Importance
Kingman Adopts Semi-Annual Financial Reporting

Kingman Adopts Semi-Annual Financial Reporting

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2026) - Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: KGSSF) (FSE: 47A1) ("Kingman" or the "Company") announces that its Board of Directors has approved the Company's election to rely on Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order") issued by the Canadian Securities Administrators ("CSA").

Related Symbols 1
KGS KGS
Source: Newsfile Corp
Visit Source
0 0 0
Read More
Comment